Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~De novo subjects:~* Seeking treatment for opioid use disorder (OUD) and for the previous 3 months meet the Diagnostic and Statistical Manual 5 (DSM-5) criteria for moderate or severe OUD~* Appropriate candidate for opioid partial-agonist treatment~* BMI between 18 and 35, inclusive~Roll-over subjects:~* Completed RB-US-13-0001~Exclusion Criteria:~De novo subjects:~* Current diagnosis, other than OUD, requiring chronic opioid treatment~* Current substance use disorder with regard to substances other than opioids, cocaine, cannabis, tobacco or alcohol~* Received medication-assisted treatment for OUD in the 90 days prior to informed consent~* Use (within past 30 days prior to informed consent) or positive urine drug screen (UDS) at screening for barbiturates, benzodiazepines,methadone or buprenorphine~* Treatment for OUD required by court order~* History of recent suicidal ideation or attempt~Roll over subjects:~* Experienced major protocol deviations or adverse events in RB-US-13-0001 which could potentially compromise subject safety~* Discontinued early from study RB-US-13-0001

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Roll-over Subjects (Type: EXPERIMENTAL): Subjects who completed RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 6 months in the Treatment period.
- De Novo Subjects (Type: EXPERIMENTAL): Subjects who did not participate in RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 12 months in the Treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).